Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

All Fate Therapeutics, Inc. Articles

Fate Therapeutics to Webcast Conference Call Reporting Q3 2020 Financial Results Nov. 5th At 2 PT

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at...

Fate Therapeutics Announces Completion of Public Offering of Common Stock At $28.31/share & Full Exercise of Underwriters’ Option to Purchase Additional Shares

Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.  The Company has established a leadership position in the cl...

Fate Therapeutics (FATE) Shares Jump In Aftermarket Trading Post Announcing Worldwide Collaboration with Janssen

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today a global collaboration and option agreement with Janssen Biotech, Inc. (Janssen), one of the Jansse...

Fate Therapeutics (FATE) Hits New All-Time High During Investor Conference Schedule

Shares of Fate Therapeutics, Inc. (FATE) hit an all-time new high today reaching $30.60/share which puts an approximate $2.3 Billion Market Cap. The 52-wk range is $12.59 - 30.60. Fate is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies f...

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us